US Price Erosion Dents Alembic
Site Re-Inspection Springs Fresh Challenge As Company Remains Bullish Overall On US
Challenging phase for Alembic as continued price erosion in the US hurts earnings, while a compliance re-inspection by the FDA at an injectables site results in 10 observations. Investors believe US sales may have bottomed out at current levels but can the Indian firm bounce back quickly?
